Types of multiple sclerosis and personal risk: what relapses and progression change

RRMS, SPMS, and PPMS are not three severity grades arranged from mild to severe. They describe the pattern of disease over time. A useful description also states whether inflammatory activity or functional progression has been observed and over what interval. The label supports communication; it does not determine an individual's entire future.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

In relapsing-remitting MS, or RRMS, recognizable attacks are followed by varying degrees of recovery. Remission does not guarantee that every function returns to its previous level. Nor does a good recovery independently establish that monitoring or maintenance treatment is unnecessary.
Clinically isolated syndrome, or CIS, concerns a first clinical event compatible with central nervous system demyelination. Whether MS can already be diagnosed depends on the remaining evidence. Under the 2024 McDonald revision published in 2025, some patients can meet diagnostic requirements without waiting for another typical attack. An older CIS label may therefore merit reassessment. Revised McDonald criteria
Request a record of the current course, the interval used to assess activity and progression, the supporting observations, and the treatment goal. A regulatory label may use relapsing MS as an umbrella covering several clinical situations. Translation should not silently narrow or expand that meaning; the receiving clinician should check the proposed medicine's Chinese indication.

Quick answer

Full guide

Risk needs a similarly precise question. Factors associated with developing MS are different from factors relevant to another relapse, accumulating disability, or an adverse effect of treatment. Clarifying which outcome is being discussed prevents family history, an MRI finding, and infection risk from becoming one vague category.

Relapsing-remitting MS describes a pattern of attacks and recovery

In relapsing-remitting MS, or RRMS, recognizable attacks are followed by varying degrees of recovery. Remission does not guarantee that every function returns to its previous level. Nor does a good recovery independently establish that monitoring or maintenance treatment is unnecessary.

International course descriptions incorporate clinical attacks, imaging activity, and progression to improve communication and treatment decisions. They describe observed disease behaviour rather than immutable biological categories established by a single laboratory test. Original consensus revising MS clinical-course descriptions

Record what each attack actually changed: whether admission was required, which function was affected, and what difficulty remained. Two people with the same attack count may have very different burdens. Frequency alone cannot capture the consequences of incomplete recovery or the effect on daily responsibilities.

Secondary progression requires a view of the earlier course

Secondary progressive MS, or SPMS, generally describes gradual functional deterioration after a preceding relapsing-remitting course. The transition may become apparent through serial observations rather than on one exact date. Incomplete recovery from a recent attack, infection, and reduced conditioning can complicate assessment.

SPMS may still include relapses or MRI activity. Conversely, wheelchair use alone does not establish the course or justify changing the label to fit a medicine. Ask for the clinical evidence behind the classification and for a separate description of current activity.

The modifiers active and progressing require a time frame. A 2020 clarification of the course descriptions emphasizes this and distinguishes general worsening from progression. A note stating only “inactive” without its observation interval or supporting evidence may be insufficient for the next treating team. Clarification of MS course terminology

Primary progressive MS does not mean there are no options

Primary progressive MS, or PPMS, has a predominantly progressive course from the outset rather than a preceding typical relapsing-remitting phase. Other causes of chronic spinal-cord or neurological impairment must still be considered. Walking that has gradually worsened over a year is not enough by itself to diagnose PPMS.

Disease-modifying treatment can be discussed in suitable patients. The Chinese ocrelizumab label approved in 2025 includes adult PPMS as well as specified relapsing forms of MS. The course therefore matters when checking indications, while individual infection risks, other illnesses, and monitoring capacity remain separate considerations. Chinese ocrelizumab prescribing information

Progressive disease also warrants symptom treatment, rehabilitation, and assessment of useful equipment. Slowing a particular form of progression and improving sleep, continence, spasticity, or transfer safety are different goals. Lack of suitability for one DMT does not remove the need for other effective aspects of care.

Absence of relapses does not cover every kind of deterioration

Progression independent of relapse activity is often abbreviated PIRA. Research using data from randomized trials has highlighted its contribution to disability accumulation in relapsing MS. Functional change therefore deserves attention before a person is formally described as having a progressive course. Original analysis of PIRA in relapsing MS

A slow day is not automatically a PIRA event. Research definitions specify measurement and confirmation conditions and account for the relationship to attacks. Clinical review must also consider temporary fluctuation and treatable causes. A large 2025 study examined standardizing PIRA definitions, illustrating why different methods can affect comparisons. Study of standardized PIRA definitions

Choose a few personally meaningful activities to track, such as reaching a bus stop, using utensils, or reading for work. Record a persistent change and relevant circumstances. The clinician can decide whether formal testing is useful; patients do not need to classify each change with a research term.

Place CIS and RIS within the current diagnostic framework

Clinically isolated syndrome, or CIS, concerns a first clinical event compatible with central nervous system demyelination. Whether MS can already be diagnosed depends on the remaining evidence. Under the 2024 McDonald revision published in 2025, some patients can meet diagnostic requirements without waiting for another typical attack. An older CIS label may therefore merit reassessment. Revised McDonald criteria

Radiologically isolated syndrome, or RIS, describes a particular imaging context without a corresponding typical clinical event. Revised RIS criteria published in 2023 refined identification and risk assessment. They do not encompass every incidental white-matter spot. Revised RIS diagnostic criteria

Current review should also consider whether a person meets the newer MS diagnostic pathways. It is inaccurate to say that every RIS presentation can only be observed or can never meet MS criteria. Equally, not every incidental finding requires immediate medication. Ask which requirements are met and what risk the proposed treatment or observation plan addresses.

Assess future disease risk from a combination of evidence

Recent activity, incomplete recovery, involvement of important anatomical regions, and functional change may influence the treatment discussion. No single feature precisely forecasts an individual's outcome. MRI findings need appropriate interpretation rather than conversion into an unexplained high-risk label. 2024 diagnostic MRI consensus

The 2025 early high-efficacy treatment consensus encourages serious consideration of timing and disease control while retaining individualized benefit-risk assessment. A higher perceived disease risk does not make infection concerns, pregnancy plans, or practical limitations irrelevant. The proposed strategy should explain how both disease and treatment risks will be managed. Early high-efficacy treatment consensus

When given a percentage, establish the population, follow-up period, and outcome. Another relapse, MRI activity, needing a walking aid, and leaving employment are not interchangeable endpoints. A trustworthy group estimate can inform discussion without becoming a personal certainty.

Understand EBV and genetic research without assigning blame

A large longitudinal study strengthened evidence connecting Epstein–Barr virus infection with subsequent MS. It does not mean a positive EBV antibody result diagnoses MS or that treating established MS simply requires eliminating a virus. Evidence about disease origin and evidence supporting an individual treatment are different questions. Longitudinal EBV and MS study

Genetic research has identified many susceptibility-associated variants and immune-related pathways. MS is not a simple single-gene condition, and an affected parent does not mean a child will inevitably develop it. Family concerns deserve a discussion based on the actual history rather than a prediction made from a few commercial genetic results. Original MS genetic susceptibility map

Neither line of research supports blaming a patient for insufficient optimism or asking a family to identify the one lifestyle decision that caused the disease. Attention is better directed toward current care choices and practical changes that can be supported.

Address modifiable factors with evidence and realistic expectations

Smoking research supports offering cessation help as part of MS care. A UK register study examined changes associated with stopping smoking, but an observational finding cannot promise a particular person's recovery. Ask for assistance that addresses habits, environment, and difficulties maintaining the change. Smoking cessation and MS progression cohort study

Vitamin D evidence is also developing. The 2025 D-Lay MS trial found benefit for a composite disease-activity endpoint, including MRI activity, in a selected early-disease population. Individual clinical secondary outcomes, including relapse, did not show the same statistically significant result. This does not establish that all people with MS should replace DMT with unsupervised high-dose supplements. D-Lay MS randomized trial

Testing and supplementation should take account of nutrition, bone health, kidney issues, and current care. Online regimens may omit the screening and monitoring conditions used in research. A claim that a diet or supplement removes all future risk needs evidence for the relevant population and outcome.

Make the classification useful at a China consultation

Request a record of the current course, the interval used to assess activity and progression, the supporting observations, and the treatment goal. A regulatory label may use relapsing MS as an umbrella covering several clinical situations. Translation should not silently narrow or expand that meaning; the receiving clinician should check the proposed medicine's Chinese indication.

If two hospitals use different classifications, compare the disease history and information available to each before choosing the label that sounds less alarming. Missing records can be added and assessments can change with evidence. The decision that matters is which risks call for action now, what remains under observation, and how the next review will determine whether the plan still fits.